

BIOPHYTIS to Present Key Research Findings on Company's Two Lead Compounds at Upcoming Scientific Conferences

- Overview of Planned Phase 2b Clinical Trial of BIO 101 in Sarcopenic Obesity to be Presented at International Conference on Frailty and Sarcopenia Research 2016
- Pre-Clinical Data Demonstrating Potential of BIO 201 as an Effective Oral Treatment for Dry AMD to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting

Romainville (France), Boston (Massachusetts), April 12, 2016 – BIOPHYTIS (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced today that posters related to the Company's two lead compounds, BIO 101 for Sarcopenic Obesity and BIO 201 for Dry AMD, will be presented at the International Conference on Frailty and Sarcopenia Research (ICFSR) 2016 in April, and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May, respectively.

Details of the presentations are below.

ICFSR - April 28-29, 2016, Philadelphia, Pennsylvania

Poster #: 53
Title: A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BIO101 on Sarcopenic Obesity
Date: Thursday, April 28, 2016
Location: Pennsylvania Convention Center
Presenter: Waly Dioh, Ph.D., Director of Clinical Development, Biophytis

ARVO - May 1-5, 2016, Seattle, Washington

Posterboard #: B0291
Abstract #: 1119 - B0291
Title: BIO201: A New Drug Candidate for the Treatment of Dry AMD
Session Name: New Drugs
Date: Sunday, May 1, 2016
Presentation Time: 3:15 – 5:00 PM
Location: Washington State Convention Center
Presenter: Valérie Fontaine, Ph.D., Senior Scientist, Institut de la Vision

About BIOPHYTIS :

BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry age-related macular degeneration (AMD).

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime.

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.



BIOPHYTIS
Stanislas VEILLET
CEO
contact@biophytis.com
Tel : +33 1 41 83 66 00

Milestones
Bruno ARABIAN
barabian@milestones.fr
Tel : +33 1 83 62 34 84
Mob : +33 6 87 88 47 26

LifeSci Advisors
Chris MAGGOS
Managing Director, Europe
chris@lifesciadvisors.com
Tel : +41 79 367 6254